Management of patients presenting with acute psychotic episodes of schizophrenia
- PMID: 19320529
- DOI: 10.2165/00023210-200923030-00002
Management of patients presenting with acute psychotic episodes of schizophrenia
Abstract
The initial management of patients with schizophrenia presenting to psychiatric emergency departments with an acute psychotic episode requires rapid decisions to be made by physicians concerning the treatment of individuals who are likely to be relatively uncooperative, agitated and lacking insight. The treatment decision must be adapted to the individual characteristics and needs of each patient. This article reviews the issues from the perspective of the initial management of acute psychosis as it is currently practised in Europe, and discusses the pragmatic implications for initial treatment decisions and the elaboration of a long-term treatment plan. Initially, administration of antipsychotics to control psychotic symptoms and benzodiazepines to control agitation represents the cornerstone of treatment. Oral medication is preferable to injectable forms wherever possible, and atypical antipsychotics are to be preferred over conventional agents because of their lower risk of extrapyramidal adverse effects, which are a major determinant of poor adherence to treatment. Whatever antipsychotic is chosen by the physician during the initial period, it is likely that it will need to be continued for many years, and it is thus important to take into account the long-term safety profile of the drug chosen, particularly in relation to extrapyramidal adverse effects, metabolic complications and quality of life. Building a therapeutic alliance with the patient and his/her family or carers is an important element that should be included in the initial management of psychosis. The long-term goal should be to minimize the risk of psychotic relapse through adequate treatment adherence.
Similar articles
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. Encephale. 2013. PMID: 23541914 French.
-
Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.J Clin Psychiatry. 2003;64 Suppl 19:13-8. J Clin Psychiatry. 2003. PMID: 14728085 Review.
-
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.J Clin Psychopharmacol. 2014 Feb;34(1):124-8. doi: 10.1097/JCP.0000000000000050. J Clin Psychopharmacol. 2014. PMID: 24346752 Clinical Trial.
-
Pharmacological management of acutely agitated schizophrenic patients.Curr Pharm Des. 2005;11(19):2471-7. doi: 10.2174/1381612054367472. Curr Pharm Des. 2005. PMID: 16026300 Review.
Cited by
-
Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis.Drugs Context. 2024 Aug 5;13:2024-4-4. doi: 10.7573/dic.2024-4-4. eCollection 2024. Drugs Context. 2024. PMID: 39131604 Free PMC article. Review.
-
Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.AAPS PharmSciTech. 2014 Dec;15(6):1598-602. doi: 10.1208/s12249-014-0189-5. Epub 2014 Aug 21. AAPS PharmSciTech. 2014. PMID: 25142821 Free PMC article.
-
Genetic markers of early response to lurasidone in acute schizophrenia.Pharmacogenomics J. 2025 Feb 20;25(2):3. doi: 10.1038/s41397-024-00360-z. Pharmacogenomics J. 2025. PMID: 39979276 Free PMC article.
-
Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia.Sci Rep. 2025 Feb 7;15(1):4663. doi: 10.1038/s41598-025-85832-3. Sci Rep. 2025. PMID: 39920141 Free PMC article.
-
Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.Patient Prefer Adherence. 2015 Sep 16;9:1333-41. doi: 10.2147/PPA.S89748. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 26396505 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical